Pricing and Reimbursement in Key Asia Pacific Markets

Publication Date	January 2009
Publisher	Datamonitor
Product Type	Report
Pages	79
ISBN Number	not applicable
Product Code	DAT14127

Buy this product or for assistance call +44 20 7060 7474

PDF £2,285.00$3801 | €2557

FAX Order above formats by FAX

Summary

Introduction

With the Asia-Pacific markets growing rapidly, they are becoming increasingly attractive for Pharma to enter. However, a number of key P&R developments and reforms are set to change the healthcare environment in the next few years, as healthcare is made more accessible to the poor and elderly.

Scope

Insight into pricing and reimbursement strategies in Australia, Singapore, China and Hong Kong

Analysis of drivers and barriers for entering Australia, Singapore, China and Hong Kong

Overview of healthcare systems in Australia, Singapore, China and Hong Kong

Identification of trends shaping national P&R strategies and their impact on branded Pharma

Highlights

In Australia, a high level of evidence is needed to show clinical and cost effectiveness, thus clearly pointing to a barrier for entering the Australian market. It is essential that a new medicine is cost effective against the standard of care, therefore solid head-to-head clinical trial data must be presented to have a successful listing.

Recent changes by the Chinese National Development and Reform Commission (NDRC) means that the financial rewards for the multinationals will be jeopardized. The pricing authority has planned another round of price reductions, but for the first time, this will also affect imported drugs.

Singapore's affluent population translates into high per capita spending on healthcare and a preference for branded drugs. Its healthcare financing system based on co-payments discourages excessive consumption and acts as a measure of cost-containment.

Reasons to Purchase

Understand the recent changes in the P&R environment in the key Asia-Pacific markets

Analyze recent trends in healthcare in Asia-Pacific and the impact on branded pharma

In-depth and up to date information on P&R regulations through interviewing local industry executives

Content

Chapter 1 Executive Summary
- Scope Of The Report
- Interviewed Pricing And Reimbursement Executives
Key Findings
Chapter 2 Overview Of Asia Pacific P&r
- Pricing And Reimbursement Strategies In Australia, Singapore, China And Hong Kong
- Health Insurance In Australia, Singapore, China And Hong Kong
- Comparing Efficiency Across Healthcare Systems
- Reimbursement In Asia-Pacific Region
- Patient Co-Pays
- Formulary Positive/Negative Lists
- Volume Limitations
- Pharmacoeconomics
- Risk-Sharing
- Pharmacist Substitution
- Pricing Strategies In Asia-Pacific
- Drivers And Resistors For Pharma Companies Entering The Australia, China And Singapore Branded Pharmaceutical Markets
- Australia - Becoming More Appealing For Big Pharma
- China - Enter With Caution
- Singapore - A Thriving Environment For Foreign Investment
Chapter 3 Australia-Specific P&r Measures
- Healthcare System In Australia
- Healthcare Expenditure In Australia Has Remained Stable
- Healthcare Reforms Aim At Improving Hospitals And Health Outcomes
- Access To Healthcare Needs To Be Improved In Rural Areas
- Poor Access To Healthcare In Rural Communities
- Healthcare Discrimination Against Indigenous People Needs To Be Addressed
- Physician Shortages In Rural Areas Is An Obstacle To Access To Healthcare
- Health Insurance Is Dominated By The Public Sector Although This Is Likely To Change
- Public Health Insurance In Australia
- Private Health Insurance In Australia
- Pricing And Reimbursement In Australia
- Prices For Prescription Drugs Are Low
- Determining Drug Cost-Effectiveness
- Reference Pricing Is Based On Stringent Pharmacoeconomics
- New Drug Price Reforms Reward Innovation
- Reimbursement In Australia Is Extensive
Chapter 4 China-Specific P&r Measures
- Healthcare System In China
- Healthcare Expenditure Has Grown Significantly
- Healthcare Reforms Are Aiming For Universal Healthcare Coverage
- Access To Healthcare Services Is Difficult For The Poor And The Rural Population
- Health Insurance Coverage Is Rising In Both Urban And Rural Areas But Is Insufficient
- The Urban Employee Basic Medical Insurance System Has Improved Healthcare Coverage In Cities
- Despite Rising Coverage, The Benefits Of Rural Health Insurance Are Questionable
- Urban Residence Insurance Scheme Offers Basic Health Insurance To The Unemployed
- Pricing And Reimbursement In China
- Price Cuts Threaten To Reduce Manufacturers' Profit Margins
- Heavy Price Cuts Have Been A Common Strategy In The Past To Reduce Healthcare Costs
- Prices Of Drugs Sold In Hospitals Are Over Inflated
- Reimbursement Is Negotiated At Local Level
- Healthcare System In Hong Kong
- Healthcare Expenditure In Hong Kong
- Healthcare Reforms Must Be Updated To Keep Up With The Evolving Needs Of The Population
- The Harvard Report Aimed At Improving Healthcare Equity And Efficiency
- Recent Reforms Aim To Further Improve Efficiency And Contain Costs
- Pricing And Reimbursement In Hong Kong
- Reimbursement Does Not Cover Novel Expensive Drugs
- High Drug Prices Results In Abuse Of Free Pricing System
Chapter 5 Singapore-Specific P&r Measures
- Healthcare System In Singapore
- Healthcare Expenditure Is Low But Sufficient
- Health Insurance
- Medisave Provides Universal Coverage
- Medishield Offers Protection Against Catastrophic Events
- Medifund Operates As A Safety Net
- Eldershield Covers Against Severe Disability
- Can The Successful 3m Framework Be Replicated?
- Pricing And Reimbursement In Singapore
- Pricing System In Singapore Rewards Innovation
- Reimbursement Is Dependent On The Level Of Care
Chapter 6 Bibliography
- Publications And Online Articles
- Conference Literature
- Datamonitor Resources
Appendix
List Of Tables
- Table 1: Key Healthcare Expenditure Indicators For Australia And The Us, 2005
- Table 2: Coverage Of Public Health Insurance In Australia
- Table 3: Coverage Of Private Health Insurance In Australia
- Table 4: Examples Of Drugs In The New Pbs Formularies, As Of September 11, 2007
- Table 5: Several Ministerial-Level Agencies Have Varying Degrees Of Authority Over Healthcare In China
- Table 6: Key Healthcare Expenditure Indicators For China And The Us, 2005
- Table 7: Key Healthcare Expenditure Indicators For Singapore And The Us, 2005
- Table 8: Medical Savings Account Schemes In Shanghai And Singapore
- Table 9: Exchange Rates, December 2008
List Of Figures
- Figure 1: Differences In Public-Private Healthcare Expenditures In Australia, China, Singapore And The Us, 2005
- Figure 2: Which Country Has The Most Successful And Cost-Effective Healthcare System?
- Figure 3: Drivers And Resistors For Branded Pharma Entering The Australia, China And Singapore Markets, 2009
- Figure 4: The Decision-Making Process For Listing A Drug On The Pbs
- Figure 5: Several Cost Containment Measures Exist In Australia
- Figure 6: Equity Must Be Addressed To Ensure Equitable Access To Healthcare In China, 2008
- Figure 7: Insurance Reforms In China, 1993-2007
- Figure 8: Reimbursement Drug List Defines The Coverage Level For Drug Insurance In China
- Figure 9: Healthcare In Hong Kong Is Provided Through Primary, Secondary Or Tertiary Care
- Figure 10: Drug Subsidy Levels In Singapore